GlassScriptPhysician profile
Thomas J Militana
NPI 1578666582
$9,279.29
in general payments reported to CMS, 2019-2025
23 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,676 · 2020: $777 · 2021: $1,828 · 2022: $1,709 · 2023: $1,061 · 2024: $712 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,793.63 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Novartis Pharmaceuticals Corporation | $617.42 | 2019-2023 | Leqvio |
| Astrazeneca Pharmaceuticals LP | $611.91 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $448.85 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $434.38 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $368.83 | 2021-2024 | Austedo, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.14 | 2019-2020 | |
| Abbvie INC. | $311.45 | 2021-2025 | |
| Lilly USA, LLC | $140.78 | 2022 | |
| Endo Pharmaceuticals INC. | $127.43 | 2019-2023 | Aveed |
| Axsome Therapeutics, INC. | $125.00 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $122.91 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.94 | 2023 | Trulance |
| Gilead Sciences, INC. | $116.14 | 2021 | |
| Merck Sharp & Dohme LLC | $107.14 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $101.82 | 2020-2022 | |
| Lundbeck LLC | $92.66 | 2025 | Vyepti |
| Avanir Pharmaceuticals, INC. | $88.25 | 2019-2021 | |
| Tactile Systems Technology INC | $67.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.75 | 2022-2023 | |
| Exact Sciences Corporation | $43.38 | 2024-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $27.95 | 2024 | Yupelri |
| Genentech USA, INC. | $24.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Militana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.